Laboratory Detection of Haemophilus influenzae with Decreased Susceptibility to Nalidixic Acid, Ciprofloxacin, Levofloxacin, and Moxifloxacin Due to gyrA and parC Mutations

Journal of Clinical Microbiology

Volumn 42, Issue 3, 2004, Pages 1185-1191

  Pérez Vázquez, María ^a   Román, Federico ^a   Aracil, Belén ^a   Cantón, Rafael ^b   Campos, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DIFFUSION; DILUTION; GENE MUTATION; GYRA GENE; HAEMOPHILUS INFLUENZAE; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AZA COMPOUNDS; BASE SEQUENCE; CIPROFLOXACIN; DNA GYRASE; DNA PRIMERS; DNA TOPOISOMERASE IV; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; OFLOXACIN; POLYMERASE CHAIN REACTION; QUINOLINES;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; NEGIBACTERIA;

EID: 12144287623     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.3.1185-1191.2004     Document Type: Article

References (30)

1. Barriere, S. L., and J. Hindler. 1993. Ciprofloxacin resistant Haemophilus influenzae in a patient with chronic lung disease. Ann. Pharmacother. 27:309-310.
2. Barry, A. L., J. H. Jorgensen, D. J. Hardy, S. D. Allen, C. N. Baker, P. C. Fuchs, and J. C. McLaughlin. 1992. Interpretive criteria and quality control parameters for testing susceptibility of Haemophilus influenzae to enoxacin, ofloxacin, and temafloxacin. J. Clin. Microbiol. 30:3013-3015.
3. Bastida, T., M. Pérez-Vázquez, J. Campos, M. C. Cortés-Lletget, F. Román, F. Tubau, A. G. de la Campa, and C. Alonso-Tarrés. 2003. Therapeutic failure in a case of pneumonia due to levofloxacin-resistant Haemophilus influenzae. Emerg. Infect. Dis. 91:1476-1478.
4. Biedenbach, D. J., and R. N. Jones. 2002. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. Diagn. Microbiol. Infect. Dis. 43:323-326.
5. Bremón, A. R., M. Ruiz-Tovar, B. P. Gorricho, P. D. de Torres, and R. L. Rodríguez. 2000. Non-hospital consumption of antibiotics in Spain: 1987-1997. J. Antimicrob. Chemother. 45:395-400.
6. Brenwald, N., J. M. Andrews, G. Jevons, and R. Wise. 2003. Detection of ciprofloxacin resistance in Haemophilus influenzae using nalidixic acid and BSAC methodology. J. Antimicrob. Chemother. 51:1311-1312.
7. Campos, J., F. Román, M. Georgiou, C. García, R. Gómez-Lus, R. Cantón, H. Escobar, and F. Baquero. 1996. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J. Infect. Dis. 174:1345-1347.
8. Corkill, J. E., A. Percival, P. McDonald, and A. I. Bamber. 1994. Detection of quinolone resistance in Haemophilus ssp. J. Antimicrob. Chemother. 34:841-844.
9. Crump, J. A., T. J. Barret, J. T. Nelson, and F. J. Angulo. 2003. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin. Infect. Dis. 37:75-81.
10. Davidson, R., R. Calvancanti, J. Brunton, D. J. Bast, J. C. de Acevedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
11. Deguchi, T., T. Kawamura, M. Yasuda, M. Nakano, H. Fukuda, H. Kato, N. Kato, Y. Okano, and Y. Kawada. 1997, In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Antimicrob. Agents Chemother. 41:1609-1611.
12. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
13. Fleischmann, R. D., M. D. Adams, O. White, R. A. Clayton, E. F. Kirkness, A. R. Kerlavage, C. J. Bull, J. F. Tomb, B. A. Dougherty, J. M. Merrick, et al. 1995. Whole-genome random sequencing and assembly of H. influenzae Rd. Science 269:449-604.
14. Galanakis, N., H. Giamarellou, T. Moussas, and E. Dounis. 1997. Chronic osteomyelitis caused by multi-resistant gram-negative bacteria: evolution of treatment with newer quinolones after prolonged follow-up. J. Antimicrob. Chemother. 39:241-246.
15. García-Rodriguez, J. A., F. Baquero, J. Garcia de Lomas, and L. Aguilar. 1999. Antimicrobial susceptibility of 1422 H. influenzae isolates from respiratory tract infections in Spain results of 1-year multicenter surveillance study. Infection 27:265-267.
16. Georgiou, M., R. Muñoz, F. Román, R. Cantón, R. Gómez-Lus, J. Campos, and A. De la Campa. 1996. Ciprofloxacin-resistant Haemophilus influenzae possesses mutations in analogous positions of GyrA and ParC. Antimicrob. Agents Chemother. 40:1741-1744.
17. Groeneveld, K., L. van Alphen, P. P. Ejik, G. Vischers, H. M. Jansen, and H. C. Zanen. 1990. Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment of persistence. J. Infect. Dis. 161:512-517.
18. Hakanen, A., P. Kotilainen, J. Jalava, A. Siitonen, and P. Huovinen. 1999. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J. Clin. Microbiol. 37:3572-3577.
19. Jones, M. E., A. M. Staples, I. Critchley, C. Thornsberry, P. Heize, H. D. Engler, and D. F. Sahm. 2000. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob. Agents Chemother. 44:2645-2652.
20. Lázaro, E., M. Madurga and F. J. de Abajo. 2002. Evolución del consumo de antibióticos en España, 1985-2000. Med. Clin. (Barcelona) 118:561-568.
21. Moniot-Ville, N., J. Guigert, N. Moreau, F. Acar, E. Collatz, and L. Gutman. 1991. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob. Agents Chemother. 35:519-523.
22. Mouton, J. W. 2002. Breakpoints: current practice and future perspectives. Int. J. Antimicrob. Agents 19:323-331.
23. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement M100-S12. NCCLS, Wayne, Pa.
24. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A5. NCCLS, Wayne, Pa.
25. Pérez-Vázquez, M., F. Román, M. C. Varela, R. Cantón, and J. Campos. 2003. Activities of thirteen quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resístance. J. Antimicrob. Chemother. 51:147-151.
26. Piddock, L. J., Y. Fang Jin, M. A. Webber, and M. J. Everett. 2002. Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2276-2278.
27. Ruiz, J., J. Gómez, M. N. Navia, A. Ribera, J. M. Sierra, F. Marco, J. Mensa, and J. Vila. 2001. High prevalence of nalidixic resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn. Microbiol. Infect. Dis. 42:257-261.
28. Sanchez, L., W. Pan, M. Viñas, and H. Nikaido. 1997. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. 179:6855-6857.
29. Sewell, D. L., A. L. Barry, S. D. Allen, P. C. Fuchs, J. H. Jorgensen, and F. Tenover. 1995. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628). Diagn. Microbiol. Infect. Dis. 21:175-179.
30. Vila, J., J. Ruiz, F. Sánchez, F. Navarro, B. Mirelis, M. T. Jiménez de Anta, and G. Prats. 1999. Increase in quinolone resistance in Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob. Agents Chemother. 43:161-162.